Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 13.78 Delayed Data As of Sep 22 |  +0.29 / +2.15%Today’s Change | 8.67 Today|||52-Week Range 14.55 | +28.79% Year-to-Date |
| Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III Sep 21 / Zacks.com - Paid Partner Content | Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU Sep 18 / Zacks.com - Paid Partner Content |
| Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD Sep 19 / Zacks.com - Paid Partner Content |
| Previous close | 13.49 |
| Today’s open | 13.47 |
| Day’s range | 13.45 - 13.81 |
| Volume | 344,483 |
| Average volume (3 months) | 888,901 |
| Market cap | $1.5B |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +121.89% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +117.48% |
| P/E ratio | 16.8 |
| Price/Sales | 8.95 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| PCRXPacira Pharmaceutica... | +0.75 | +2.06% |
| EBSEmergent BioSolution... | +0.67 | +1.78% |
| MYOKMyoKardia Inc | -2.05 | -4.34% |
| LXRXLexicon Pharmaceutic... | -0.42 | -3.28% |
| Next reporting date | November 1, 2017 |
| EPS forecast (this quarter) | $0.32 |
| Annual revenue (last year) | $147.4M |
| Annual profit (last year) | $59.5M |
| Net profit margin | 40.39% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Michael W. Aguiar |
Chief Financial Officer & Senior Vice President Eric d'Esparbes |
Corporate headquarters Brisbane, California |
